Bristol Has Appetite For Obesity: Firm To License Solvay Phase I Cannabinoid Antagonist
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will jointly develop and commercialize SLV319. Potential inroad into obesity market aligns with Bristol's long-term focus on "high-potential disease areas," company says.
You may also be interested in...
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Fournier's co-marketing agreement with Abbott for the lipid-lowering product will remain unchanged following Solvay's €1.3 bil. acquisition of the French company. Solvay will build a new cardio-metabolic division from Fournier, to be headquartered in Paris.
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Fournier's co-marketing agreement with Abbott for the lipid-lowering product will remain unchanged following Solvay's €1.3 bil. acquisition of the French company. Solvay will build a new cardio-metabolic division from Fournier, to be headquartered in Paris.
FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says
Patients with a body mass index exceeding 25, rather than BMI>27, should be allowed in trials, PhRMA says. Revised guidance should also eliminate the need for a weight-loss attempt immediately before enrollment, the association suggests.